Ladenburg Thalmann & Co. Keeps a Hold Rating on Savara Inc (SVRA)

By Jason Carr

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Hold rating on Savara Inc (SVRAResearch Report), with a price target of $1.00. The company’s shares closed last Monday at $1.03, close to its 52-week low of $1.01.

According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -14.2% and a 27.5% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Savara Inc with a $8.00 average price target.

See today’s analyst top recommended stocks >>

Based on Savara Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $21.94 million. In comparison, last year the company had a GAAP net loss of $12.56 million.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SVRA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.